Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Fallopian Tube Undifferentiated Carcinoma

Mayo ClinicSmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

72 Active assets in the Fallopian Tube Undifferentiated Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Women's Hospital School Of Medicine Zhejiang University
Phase 3BBB
TAMOXIFEN
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 3BB
Cyclophosphamide
Mayo Clinic
Phase 2BB
Pembrolizumab
Roswell Park Cancer Institute
Phase 2BB
Olaparib
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →